Beximco Pharmaceuticals Ltd.
19th May 2009
Beximco Pharmaceuticals exports Oseltamivir capsules to Latin and Central America
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”) today announces that it has commenced supplying Oseltamivir capsules, Oseflu® (BPL′s generic version of Tamiflu®), to Latin and Central American countries, the regions most affected by the recent H1N1 swine flu (influenza A) outbreak.
According to the World Health Organization (“WHO”) estimate 39 countries have officially reported 8,480 cases of influenza A (H1N1) infection, (WHO update 31, 17 May 2009). H1N1 appears to be more contagious than seasonal influenza and the new virus causing swine flu has been found to respond positively to Oseltamivir treatment.
Nazmul Hassan, Managing Director of Beximco Pharmaceuticals, commented:
“BPL is the first company from Bangladesh to help combat the swine flu outbreak in Latin & Central American countries. The Company has already supplied Oseflu® stocks to the Ministry of Health in Chile and Belize, as well as to high profile Government and non-Government agencies. We look forward to helping to combat this virus which has already affected many people across the world.”
Beximco Pharmaceuticals introduced Oseltamivir capsule Oseflu® in 2006 for the prevention and treatment of influenza including swine and bird flu. In the same year BPL supplied Oseflu® to the Bangladesh and Myanmar Governments for stockpiling to combat the Bird flu andemic. The Company has increased its Oseflu® stock to ensure further supply into other countries in the near future.
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company′s products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.